3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
6
Gynecologic
2
Thoracic
1
Genitourinary
1
Breast
1
Conditions
Breast Neoplasms
577
Triple Negative Breast Neoplasms
125
Neoplasm Metastasis
50
Breast Neoplasms, Male
28
Ovarian Neoplasms
26
Neoplasms
26
Inflammatory Breast Neoplasms
22
Carcinoma, Non-Small-Cell Lung
19
Stomach Neoplasms
14
Endometrial Neoplasms
11
Carcinoma, Ductal, Breast
11
Carcinoma, Ovarian Epithelial
10
Pancreatic Neoplasms
9
Colorectal Neoplasms
9
Melanoma
8
Lung Neoplasms
8
Parkinson Disease 4, Autosomal Dominant Lewy Body
7
HER2-positive Breast Cancer
7
Squamous Cell Carcinoma of Head and Neck
6
Prostatic Neoplasms
6
Esophageal Neoplasms
6
Carcinoma, Renal Cell
6
Uterine Cervical Neoplasms
5
Urinary Bladder Neoplasms
4
Brain Neoplasms
4
Anatomic Stage I Breast Cancer AJCC v8
4
Advanced Breast Cancer
4
Small Cell Lung Carcinoma
3
Sarcoma
3
Recurrence
3
Interventions
pembrolizumab
4
Nivolumab
3
Itraconazole
2
tucatinib
1
tremelimumab
1
regorafenib
1
pertuzumab
1
lenvatinib
1
larotrectinib
1
durvalumab
1
cemiplimab
1
brigimadlin
1
aflibercept
1
Trastuzumab
1
Ritonavir
1
Paclitaxel
1
Fulvestrant
1
Clinical Trials, Phase II as Topic
1
Carboplatin
1
Capecitabine
1
Antibodies
1
AZD9833
1
AZD5305
1
AZD 6244
1
ARX788
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Biliary Tract Neoplasms
×
Paclitaxel
×
Breast
×
Clear all
NCT04644068
2026-02-19
PETRA
AstraZeneca
Phase 1/2
Active not recruiting
702 enrolled